Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > $5.6 Billion move into big pharma by Berkshire

<< Previous

Bullboard Posts

Next >>

Comment by Snowballgrowthon Jan 08, 2021 9:31pm

111 Views

Post# 32260046

RE:RE:RE:RE:RE:RE:$5.6 Billion move into big pharma by Berkshire

Chianchin wrote: Me think Mrmugsy, Goldinvestor and wagyusteak same person and possibly paid PR for GUD Management. I sold and gone. Very bad company and same aliias promoter on board. No beleive these three alias

Another investor gone. We see some "fatigue" and impatience from investors these days.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project